Table 1.
Classification of combined antibodies
| Antigen Localization | Risk Classification | Antibody |
|---|---|---|
| Neural intracellular antigen antibody | High-risk antibodies | CV2/CRMP5 antibody, Hu/ANNA-1 antibody, SOX1/AGNA antibody, Ma2/Ta antibody, Yo/PCA-1 antibody, Ri/ANNA-2 antibody, amphiphysin antibody, PCA-2/MAP1B antibody |
| Neural surface antigen antibody | Intermediate-risk antibodies | AMPAR antibody, GABAB receptor antibody, VGCC antibody, NMDAR antibody, CASPR2 antibodya |
| Low-risk antibodies | LGI1 antibody, CASPR2 antibody, MOG antibody |
CASPR2 antibodya, only in the case of manifested as morvan syndrome CASPR2 antibody is considered as intermediate-risk antibody. AGNA: Anti-glial nuclear antibody; AMPAR:α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor; ANNA: antineuronal nuclear antibody; CASPR2: contactin-associated protein-like 2; CRMP5: collapsin response mediator protein 5; GABAB: gamma-aminobutyric acid B; LGI1: leucine-rich glioma-inactivated 1; MAP1B: microtubule associated protein 1B; MOG: myelin oligodendrocyte glycoprotein; NMDAR: N-methyl-D-aspartate receptor; PCA: Purkinje cell antibody; VGCC: voltage -gated calcium channel.